Jayne Swain

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory et al. · The Lancet Oncology · 2023 · 76 citations · Full text

Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial

Jennifer Walsh, Helen Marshall, Isabelle L Smith et al. · PLoS Medicine · 2019 · 28 citations · Full text

NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)

Zoe Craig, Jayne Swain, Emma Batman et al. · BMJ Open · 2020 · 18 citations · Full text

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

Mairéad G. McNamara, Jayne Swain, Zoe Craig et al. · EClinicalMedicine · 2023 · 18 citations · Full text

Verification of molecular subtyping of bladder cancer in the <scp>GUSTO</scp> clinical trial

Jon Griffin, Jenny Down, Lewis A. Quayle et al. · The Journal of Pathology Clinical Research · 2024 · 17 citations · Full text